Company profile: Disc Medicine
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for hematologic diseases and rare blood disorders, including Bitopertin, an oral GlyT1 inhibitor for erythropoietic porphyrias and abnormal erythropoiesis; DISC-0974, an injectable monoclonal antibody targeting hemojuvelin (HJV) to suppress hepcidin for anemias of inflammation; and DISC-3405, an injectable monoclonal antibody inhibiting TMPRSS6 to increase hepcidin for polycythemia vera and iron overload.
Products and services
- DISC-0974: An injectable monoclonal antibody targeting hemojuvelin (HJV) to suppress hepcidin production for treating anemias of inflammation, with precise HJV inhibition as its mechanism
- DISC-3405: An injectable monoclonal antibody inhibiting TMPRSS6 to increase hepcidin levels for treating polycythemia vera and iron overload diseases, leveraging TMPRSS6 blockade to elevate endogenous hepcidin
- Bitopertin: An oral inhibitor targeting glycine transporter 1 (GlyT1) to treat erythropoietic porphyrias and conditions with abnormal erythropoiesis through transporter blockade
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Disc Medicine
VarmX
HQ: The Netherlands
Website
- Description: Provider of therapeutic proteins to instantaneously restore blood clotting in bleeding patients. A spin-off from Leiden University Medical Center, VarmX develops and manufactures recombinant factor X products, including VMX-C001 (a modified recombinant human factor X) to treat severe bleeding and prevent bleeding during urgent surgery in patients on FXa-DOACs, and a pipeline with replacement and second-generation factor X candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full VarmX company profile →
Babson Diagnostics
HQ: United States
Website
- Description: Provider of retail pharmacy-based diagnostic blood testing using small-volume fingertip samples, offering the BetterWay Blood Testing service, the BD MiniDraw capillary collection system, automated sample handling technology, proprietary miniaturized assays, and a CLIA-certified laboratory for high-throughput processing and accurate results.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Babson Diagnostics company profile →
CytoPherx
HQ: United States
Website
- Description: Provider of a proprietary selective cytopheresis system for inflammation-based diseases and conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CytoPherx company profile →
HemoSonics
HQ: United States
Website
- Description: Provider of in vitro diagnostics to characterize hemostasis, featuring the Quantra Hemostasis System using patented sonorheometry (SR). Offerings include the Quantra Analyzer; QPlus and QStat cartridges to assess clot time, stiffness, fibrinogen/platelet contributions and lysis; quality controls; a desktop remote viewer; and connectivity to electronic medical records and point-of-care device data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HemoSonics company profile →
Daxor
HQ: United States
Website
- Description: Provider of medical instrumentation and biotechnology solutions, offering the BVA-100 diagnostic blood test that quantifies blood volume status and composition to aid management of medical and surgical conditions, and clinical education and support for effective use of the BVA-100 in clinical settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Daxor company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Disc Medicine
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Disc Medicine
2.2 - Growth funds investing in similar companies to Disc Medicine
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Disc Medicine
4.2 - Public trading comparable groups for Disc Medicine
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →